Supply chain assurance for healthcare and medical devices

Healthcare providers sit in NIS2 Annex I — large providers as essential entities, the highest enforcement tier, medium-sized ones as important. Most medical device manufacturers are Annex II important entities; only manufacturers of devices deemed critical during a public health emergency are placed in Annex I. Hospital operations depend on a thin, deeply specialised supply chain: EHR and PACS platforms, medical device firmware, hospital information systems, regulated cloud providers running patient data. Many of these suppliers are themselves NIS2-regulated, which means assurance work flows in both directions.

The friction is unusually high. Healthcare procurement frameworks weren’t designed around supplier cybersecurity assurance, contract cycles are long (5–10 years for major systems), and clinical risk concerns often dominate the procurement conversation in ways that crowd out cybersecurity questions until late. NIS2 changes that — the directive expects supplier assurance evidence on a tighter cadence than most healthcare buyers have ever operated.

Medical devices are subject to the EU Medical Device Regulation (MDR) concurrently with NIS2. The two regimes overlap meaningfully: MDR requires manufacturers to maintain post-market surveillance and cybersecurity vulnerability management; NIS2 Article 21(2)(d) requires healthcare providers to assess the cybersecurity posture of the medical device manufacturers they procure from. Aligned evidence shapes can satisfy both with shared artefacts — but only if the supplier-assurance programme is designed for that from the start.

National transpositions add sector-specific evidence requirements, and regulator guidance in the region increasingly adds expectations around firmware update controls, medical-device sub-processor transparency, and the lifecycle handling of legacy devices that pre-date current cybersecurity expectations.

The pattern most distinctive to healthcare is layered assurance through the medical device value chain. A hospital procures a medical device from a manufacturer; the device runs firmware from a sub-component vendor; the firmware update process runs through a cloud platform that itself has sub-processors. Article 21(2)(d) work in healthcare regularly involves second-tier and third-tier sub-processor visibility that most other sectors don’t routinely require.

EHR and PACS cloud providers are themselves Annex I — assurance work flows both ways. A hospital’s EHR vendor is being assessed by the hospital AND is being assessed by every other hospital in the country. Evidence reuse becomes both an operational necessity (you can’t answer 30 different hospital questionnaires bespoke each time) and a compliance signal (consistent evidence across customers reads as mature, inconsistent reads as cherry-picked).

Vittnor — Supply Chain Assurance for the mid-market — captures the medical device value chain: sub-processor visibility from supplier-disclosed lists at each review cycle covers the Tier 1 manufacturer plus the device firmware vendors, plus the cloud platforms behind those; reviewer-flagged changes at any layer prompt a re-review, with automated triggers shipping in V1.2 (2027). Evidence collection is anchored to NIS2 Article 21(2)(d) and shaped with MDR cybersecurity post-market surveillance in view — cross-regime evidence routing is on the v2 roadmap.

For medical device manufacturers using the supplier-side surface: one evidence library keeps every artefact current and organised, so the next hospital or integrator questionnaire starts from what you already proved — cross-buyer reuse is planned for later versions. For healthcare providers using the buyer-side surface: structured assessment for medical device firmware suppliers, decision-trace as the audit-defensibility artefact, and the Qualified Manager retainer for hospital systems without a dedicated CISO that need a NIS2-qualified voice on board papers.